Erlotinib	B:C1135135
plus	O
gemcitabine	O
versus	O
gemcitabine	O
for	O
pancreatic	O
cancer	I:C0235974
:	O
real	O
-	O
world	O
analysis	O
of	O
Korean	O
national	O
database	O
A	O
randomized	O
clinical	I:C0206034
trial	I:C0206034
has	O
found	O
that	O
the	O
addition	O
of	O
erlotinib	O
to	O
gemcitabine	O
(	O
GEM	O
-	O
E	O
)	O
for	O
pancreatic	O
cancer	I:C0235974
led	O
to	O
a	O
modest	O
increase	O
in	O
survival	O
.	O

Erlotinib	O
plus	O
gemcitabine	B:C0045093
versus	O
gemcitabine	O
for	O
pancreatic	O
cancer	I:C0235974
:	O
real	O
-	O
world	O
analysis	O
of	O
Korean	O
national	O
database	O
A	O
randomized	O
clinical	I:C0206034
trial	I:C0206034
has	O
found	O
that	O
the	O
addition	O
of	O
erlotinib	O
to	O
gemcitabine	O
(	O
GEM	O
-	O
E	O
)	O
for	O
pancreatic	O
cancer	I:C0235974
led	O
to	O
a	O
modest	O
increase	O
in	O
survival	O
.	O

Erlotinib	O
plus	O
gemcitabine	O
versus	O
gemcitabine	B:C0045093
for	O
pancreatic	O
cancer	I:C0235974
:	O
real	O
-	O
world	O
analysis	O
of	O
Korean	O
national	O
database	O
A	O
randomized	O
clinical	I:C0206034
trial	I:C0206034
has	O
found	O
that	O
the	O
addition	O
of	O
erlotinib	O
to	O
gemcitabine	O
(	O
GEM	O
-	O
E	O
)	O
for	O
pancreatic	O
cancer	I:C0235974
led	O
to	O
a	O
modest	O
increase	O
in	O
survival	O
.	O

Erlotinib	O
plus	O
gemcitabine	O
versus	O
gemcitabine	O
for	O
pancreatic	B:C0235974
cancer	I:C0235974
:	O
real	O
-	O
world	O
analysis	O
of	O
Korean	O
national	O
database	O
A	O
randomized	O
clinical	I:C0206034
trial	I:C0206034
has	O
found	O
that	O
the	O
addition	O
of	O
erlotinib	O
to	O
gemcitabine	O
(	O
GEM	O
-	O
E	O
)	O
for	O
pancreatic	O
cancer	I:C0235974
led	O
to	O
a	O
modest	O
increase	O
in	O
survival	O
.	O

Erlotinib	O
plus	O
gemcitabine	O
versus	O
gemcitabine	O
for	O
pancreatic	O
cancer	I:C0235974
:	O
real	O
-	O
world	B:C2700280
analysis	O
of	O
Korean	O
national	O
database	O
A	O
randomized	O
clinical	I:C0206034
trial	I:C0206034
has	O
found	O
that	O
the	O
addition	O
of	O
erlotinib	O
to	O
gemcitabine	O
(	O
GEM	O
-	O
E	O
)	O
for	O
pancreatic	O
cancer	I:C0235974
led	O
to	O
a	O
modest	O
increase	O
in	O
survival	O
.	O

Erlotinib	O
plus	O
gemcitabine	O
versus	O
gemcitabine	O
for	O
pancreatic	O
cancer	I:C0235974
:	O
real	O
-	O
world	O
analysis	B:C0936012
of	O
Korean	O
national	O
database	O
A	O
randomized	O
clinical	I:C0206034
trial	I:C0206034
has	O
found	O
that	O
the	O
addition	O
of	O
erlotinib	O
to	O
gemcitabine	O
(	O
GEM	O
-	O
E	O
)	O
for	O
pancreatic	O
cancer	I:C0235974
led	O
to	O
a	O
modest	O
increase	O
in	O
survival	O
.	O

Erlotinib	O
plus	O
gemcitabine	O
versus	O
gemcitabine	O
for	O
pancreatic	O
cancer	I:C0235974
:	O
real	O
-	O
world	O
analysis	O
of	O
Korean	B:C0022771
national	O
database	O
A	O
randomized	O
clinical	I:C0206034
trial	I:C0206034
has	O
found	O
that	O
the	O
addition	O
of	O
erlotinib	O
to	O
gemcitabine	O
(	O
GEM	O
-	O
E	O
)	O
for	O
pancreatic	O
cancer	I:C0235974
led	O
to	O
a	O
modest	O
increase	O
in	O
survival	O
.	O

Erlotinib	O
plus	O
gemcitabine	O
versus	O
gemcitabine	O
for	O
pancreatic	O
cancer	I:C0235974
:	O
real	O
-	O
world	O
analysis	O
of	O
Korean	O
national	B:C0015737
database	O
A	O
randomized	O
clinical	I:C0206034
trial	I:C0206034
has	O
found	O
that	O
the	O
addition	O
of	O
erlotinib	O
to	O
gemcitabine	O
(	O
GEM	O
-	O
E	O
)	O
for	O
pancreatic	O
cancer	I:C0235974
led	O
to	O
a	O
modest	O
increase	O
in	O
survival	O
.	O

Erlotinib	O
plus	O
gemcitabine	O
versus	O
gemcitabine	O
for	O
pancreatic	O
cancer	I:C0235974
:	O
real	O
-	O
world	O
analysis	O
of	O
Korean	O
national	O
database	B:C0242356
A	O
randomized	O
clinical	I:C0206034
trial	I:C0206034
has	O
found	O
that	O
the	O
addition	O
of	O
erlotinib	O
to	O
gemcitabine	O
(	O
GEM	O
-	O
E	O
)	O
for	O
pancreatic	O
cancer	I:C0235974
led	O
to	O
a	O
modest	O
increase	O
in	O
survival	O
.	O

Erlotinib	O
plus	O
gemcitabine	O
versus	O
gemcitabine	O
for	O
pancreatic	O
cancer	I:C0235974
:	O
real	O
-	O
world	O
analysis	O
of	O
Korean	O
national	O
database	O
A	O
randomized	B:C0206034
clinical	I:C0206034
trial	I:C0206034
has	O
found	O
that	O
the	O
addition	O
of	O
erlotinib	O
to	O
gemcitabine	O
(	O
GEM	O
-	O
E	O
)	O
for	O
pancreatic	O
cancer	I:C0235974
led	O
to	O
a	O
modest	O
increase	O
in	O
survival	O
.	O

Erlotinib	O
plus	O
gemcitabine	O
versus	O
gemcitabine	O
for	O
pancreatic	O
cancer	I:C0235974
:	O
real	O
-	O
world	O
analysis	O
of	O
Korean	O
national	O
database	O
A	O
randomized	O
clinical	I:C0206034
trial	I:C0206034
has	O
found	O
that	O
the	O
addition	O
of	O
erlotinib	B:C1135135
to	O
gemcitabine	O
(	O
GEM	O
-	O
E	O
)	O
for	O
pancreatic	O
cancer	I:C0235974
led	O
to	O
a	O
modest	O
increase	O
in	O
survival	O
.	O

Erlotinib	O
plus	O
gemcitabine	O
versus	O
gemcitabine	O
for	O
pancreatic	O
cancer	I:C0235974
:	O
real	O
-	O
world	O
analysis	O
of	O
Korean	O
national	O
database	O
A	O
randomized	O
clinical	I:C0206034
trial	I:C0206034
has	O
found	O
that	O
the	O
addition	O
of	O
erlotinib	O
to	O
gemcitabine	B:C0045093
(	O
GEM	O
-	O
E	O
)	O
for	O
pancreatic	O
cancer	I:C0235974
led	O
to	O
a	O
modest	O
increase	O
in	O
survival	O
.	O

Erlotinib	O
plus	O
gemcitabine	O
versus	O
gemcitabine	O
for	O
pancreatic	O
cancer	I:C0235974
:	O
real	O
-	O
world	O
analysis	O
of	O
Korean	O
national	O
database	O
A	O
randomized	O
clinical	I:C0206034
trial	I:C0206034
has	O
found	O
that	O
the	O
addition	O
of	O
erlotinib	O
to	O
gemcitabine	O
(	O
GEM	B:C0045093
-	O
E	O
)	O
for	O
pancreatic	O
cancer	I:C0235974
led	O
to	O
a	O
modest	O
increase	O
in	O
survival	O
.	O

Erlotinib	O
plus	O
gemcitabine	O
versus	O
gemcitabine	O
for	O
pancreatic	O
cancer	I:C0235974
:	O
real	O
-	O
world	O
analysis	O
of	O
Korean	O
national	O
database	O
A	O
randomized	O
clinical	I:C0206034
trial	I:C0206034
has	O
found	O
that	O
the	O
addition	O
of	O
erlotinib	O
to	O
gemcitabine	O
(	O
GEM	O
-	O
E	B:C1135135
)	O
for	O
pancreatic	O
cancer	I:C0235974
led	O
to	O
a	O
modest	O
increase	O
in	O
survival	O
.	O

Erlotinib	O
plus	O
gemcitabine	O
versus	O
gemcitabine	O
for	O
pancreatic	O
cancer	I:C0235974
:	O
real	O
-	O
world	O
analysis	O
of	O
Korean	O
national	O
database	O
A	O
randomized	O
clinical	I:C0206034
trial	I:C0206034
has	O
found	O
that	O
the	O
addition	O
of	O
erlotinib	O
to	O
gemcitabine	O
(	O
GEM	O
-	O
E	O
)	O
for	O
pancreatic	B:C0235974
cancer	I:C0235974
led	O
to	O
a	O
modest	O
increase	O
in	O
survival	O
.	O

The	O
aim	O
of	O
this	O
national	O
population	B:C1257890
-	O
based	O
retrospective	O
study	I:C0035363
was	O
to	O
compare	O
the	O
effectiveness	O
of	O
GEM	O
-	O
E	O
to	O
GEM	O
alone	O
for	O
pancreatic	O
cancer	I:C0235974
patients	O
in	O
real	O
clinical	O
practice	O
.	O

The	O
aim	O
of	O
this	O
national	O
population	O
-	O
based	O
retrospective	B:C0035363
study	I:C0035363
was	O
to	O
compare	O
the	O
effectiveness	O
of	O
GEM	O
-	O
E	O
to	O
GEM	O
alone	O
for	O
pancreatic	O
cancer	I:C0235974
patients	O
in	O
real	O
clinical	O
practice	O
.	O

The	O
aim	O
of	O
this	O
national	O
population	O
-	O
based	O
retrospective	O
study	I:C0035363
was	O
to	O
compare	O
the	O
effectiveness	O
of	O
GEM	B:C0045093
-	O
E	O
to	O
GEM	O
alone	O
for	O
pancreatic	O
cancer	I:C0235974
patients	O
in	O
real	O
clinical	O
practice	O
.	O

The	O
aim	O
of	O
this	O
national	O
population	O
-	O
based	O
retrospective	O
study	I:C0035363
was	O
to	O
compare	O
the	O
effectiveness	O
of	O
GEM	O
-	O
E	B:C1135135
to	O
GEM	O
alone	O
for	O
pancreatic	O
cancer	I:C0235974
patients	O
in	O
real	O
clinical	O
practice	O
.	O

The	O
aim	O
of	O
this	O
national	O
population	O
-	O
based	O
retrospective	O
study	I:C0035363
was	O
to	O
compare	O
the	O
effectiveness	O
of	O
GEM	O
-	O
E	O
to	O
GEM	B:C0045093
alone	O
for	O
pancreatic	O
cancer	I:C0235974
patients	O
in	O
real	O
clinical	O
practice	O
.	O

The	O
aim	O
of	O
this	O
national	O
population	O
-	O
based	O
retrospective	O
study	I:C0035363
was	O
to	O
compare	O
the	O
effectiveness	O
of	O
GEM	O
-	O
E	O
to	O
GEM	O
alone	O
for	O
pancreatic	B:C0235974
cancer	I:C0235974
patients	O
in	O
real	O
clinical	O
practice	O
.	O

Patients	O
with	O
pancreatic	B:C0235974
cancer	I:C0235974
(	O
ICD	I:C1137110
-	I:C1137110
10	I:C1137110
:	O
C25	O
)	O
with	O
prescription	O
claims	O
of	O
gemcitabine	O
or	O
erlotinib	O
between	O
Jan	O
1	O
,	O
2007	O
and	O
Dec	O
31	O
,	O
2012	O
were	O
retrospectively	O
identified	O
from	O
the	O
Korean	O
Health	O
Insurance	I:C0027452
claims	O
database	O
.	O

Patients	O
with	O
pancreatic	O
cancer	I:C0235974
(	B:C1137110
ICD	I:C1137110
-	I:C1137110
10	I:C1137110
:	O
C25	O
)	O
with	O
prescription	O
claims	O
of	O
gemcitabine	O
or	O
erlotinib	O
between	O
Jan	O
1	O
,	O
2007	O
and	O
Dec	O
31	O
,	O
2012	O
were	O
retrospectively	O
identified	O
from	O
the	O
Korean	O
Health	O
Insurance	I:C0027452
claims	O
database	O
.	O

Patients	O
with	O
pancreatic	O
cancer	I:C0235974
(	O
ICD	I:C1137110
-	I:C1137110
10	I:C1137110
:	O
C25	O
)	O
with	O
prescription	B:C1521941
claims	O
of	O
gemcitabine	O
or	O
erlotinib	O
between	O
Jan	O
1	O
,	O
2007	O
and	O
Dec	O
31	O
,	O
2012	O
were	O
retrospectively	O
identified	O
from	O
the	O
Korean	O
Health	O
Insurance	I:C0027452
claims	O
database	O
.	O

Patients	O
with	O
pancreatic	O
cancer	I:C0235974
(	O
ICD	I:C1137110
-	I:C1137110
10	I:C1137110
:	O
C25	O
)	O
with	O
prescription	O
claims	O
of	O
gemcitabine	B:C0045093
or	O
erlotinib	O
between	O
Jan	O
1	O
,	O
2007	O
and	O
Dec	O
31	O
,	O
2012	O
were	O
retrospectively	O
identified	O
from	O
the	O
Korean	O
Health	O
Insurance	I:C0027452
claims	O
database	O
.	O

Patients	O
with	O
pancreatic	O
cancer	I:C0235974
(	O
ICD	I:C1137110
-	I:C1137110
10	I:C1137110
:	O
C25	O
)	O
with	O
prescription	O
claims	O
of	O
gemcitabine	O
or	O
erlotinib	B:C1135135
between	O
Jan	O
1	O
,	O
2007	O
and	O
Dec	O
31	O
,	O
2012	O
were	O
retrospectively	O
identified	O
from	O
the	O
Korean	O
Health	O
Insurance	I:C0027452
claims	O
database	O
.	O

Patients	O
with	O
pancreatic	O
cancer	I:C0235974
(	O
ICD	I:C1137110
-	I:C1137110
10	I:C1137110
:	O
C25	O
)	O
with	O
prescription	O
claims	O
of	O
gemcitabine	O
or	O
erlotinib	O
between	O
Jan	O
1	O
,	O
2007	O
and	O
Dec	O
31	O
,	O
2012	O
were	O
retrospectively	O
identified	O
from	O
the	O
Korean	B:C0022771
Health	O
Insurance	I:C0027452
claims	O
database	O
.	O

Patients	O
with	O
pancreatic	O
cancer	I:C0235974
(	O
ICD	I:C1137110
-	I:C1137110
10	I:C1137110
:	O
C25	O
)	O
with	O
prescription	O
claims	O
of	O
gemcitabine	O
or	O
erlotinib	O
between	O
Jan	O
1	O
,	O
2007	O
and	O
Dec	O
31	O
,	O
2012	O
were	O
retrospectively	O
identified	O
from	O
the	O
Korean	O
Health	B:C0027452
Insurance	I:C0027452
claims	O
database	O
.	O

Patients	O
with	O
pancreatic	O
cancer	I:C0235974
(	O
ICD	I:C1137110
-	I:C1137110
10	I:C1137110
:	O
C25	O
)	O
with	O
prescription	O
claims	O
of	O
gemcitabine	O
or	O
erlotinib	O
between	O
Jan	O
1	O
,	O
2007	O
and	O
Dec	O
31	O
,	O
2012	O
were	O
retrospectively	O
identified	O
from	O
the	O
Korean	O
Health	O
Insurance	I:C0027452
claims	O
database	B:C0242356
.	O

To	O
be	O
included	O
in	O
the	O
study	B:C2603343
population	O
,	O
patients	O
were	O
required	O
to	O
have	O
had	O
a	O
histological	O
or	O
cytological	O
diagnosis	I:C1298647
within	O
one	O
year	O
before	O
chemotherapy	O
.	O

To	O
be	O
included	O
in	O
the	O
study	O
population	B:C1257890
,	O
patients	O
were	O
required	O
to	O
have	O
had	O
a	O
histological	O
or	O
cytological	O
diagnosis	I:C1298647
within	O
one	O
year	O
before	O
chemotherapy	O
.	O

To	O
be	O
included	O
in	O
the	O
study	O
population	O
,	O
patients	O
were	O
required	O
to	O
have	O
had	O
a	O
histological	O
or	O
cytological	B:C1298647
diagnosis	I:C1298647
within	O
one	O
year	O
before	O
chemotherapy	O
.	O

To	O
be	O
included	O
in	O
the	O
study	O
population	O
,	O
patients	O
were	O
required	O
to	O
have	O
had	O
a	O
histological	O
or	O
cytological	O
diagnosis	I:C1298647
within	O
one	O
year	O
before	O
chemotherapy	B:C3665472
.	O

Patients	O
treated	B:C0332154
with	I:C0332154
prior	O
radiotherapy	O
,	O
surgery	O
,	O
or	O
chemotherapy	O
were	O
excluded	O
to	O
reduce	O
heterogeneity	O
.	O

Patients	O
treated	O
with	I:C0332154
prior	O
radiotherapy	B:C1522449
,	O
surgery	O
,	O
or	O
chemotherapy	O
were	O
excluded	O
to	O
reduce	O
heterogeneity	O
.	O

Patients	O
treated	O
with	I:C0332154
prior	O
radiotherapy	O
,	O
surgery	B:C2081627
,	O
or	O
chemotherapy	O
were	O
excluded	O
to	O
reduce	O
heterogeneity	O
.	O

Patients	O
treated	O
with	I:C0332154
prior	O
radiotherapy	O
,	O
surgery	O
,	O
or	O
chemotherapy	B:C3665472
were	O
excluded	O
to	O
reduce	O
heterogeneity	O
.	O

Patients	O
treated	O
with	I:C0332154
prior	O
radiotherapy	O
,	O
surgery	O
,	O
or	O
chemotherapy	O
were	O
excluded	O
to	O
reduce	B:C0441610
heterogeneity	O
.	O

Overall	O
survival	O
from	O
the	O
initiation	O
of	O
therapy	B:C0087111
and	O
the	O
medical	O
costs	O
of	O
GEM	O
-	O
E	O
and	O
GEM	O
were	O
compared	O
.	O

Overall	O
survival	O
from	O
the	O
initiation	O
of	O
therapy	O
and	O
the	O
medical	O
costs	O
of	O
GEM	B:C0045093
-	O
E	O
and	O
GEM	O
were	O
compared	O
.	O

Overall	O
survival	O
from	O
the	O
initiation	O
of	O
therapy	O
and	O
the	O
medical	O
costs	O
of	O
GEM	O
-	O
E	B:C1135135
and	O
GEM	O
were	O
compared	O
.	O

Overall	O
survival	O
from	O
the	O
initiation	O
of	O
therapy	O
and	O
the	O
medical	O
costs	O
of	O
GEM	O
-	O
E	O
and	O
GEM	B:C0045093
were	O
compared	O
.	O

A	O
total	O
of	O
4,267	O
patients	O
were	O
included	O
in	O
the	O
analysis	B:C0936012
.	O

Overall	O
survival	O
was	O
not	O
significantly	O
longer	O
in	O
patients	O
treated	B:C0332154
with	O
GEM	O
-	O
E	O
(	O
median	O
6.77	O
months	O
for	O
GEM	O
-	O
E	O
vs.	O
6.68	O
months	O
for	O
GEM	O
,	O
p	O
=	O
0.0977	O
)	O
.	O

Overall	O
survival	O
was	O
not	O
significantly	O
longer	O
in	O
patients	O
treated	O
with	O
GEM	B:C0045093
-	O
E	O
(	O
median	O
6.77	O
months	O
for	O
GEM	O
-	O
E	O
vs.	O
6.68	O
months	O
for	O
GEM	O
,	O
p	O
=	O
0.0977	O
)	O
.	O

Overall	O
survival	O
was	O
not	O
significantly	O
longer	O
in	O
patients	O
treated	O
with	O
GEM	O
-	O
E	B:C1135135
(	O
median	O
6.77	O
months	O
for	O
GEM	O
-	O
E	O
vs.	O
6.68	O
months	O
for	O
GEM	O
,	O
p	O
=	O
0.0977	O
)	O
.	O

Overall	O
survival	O
was	O
not	O
significantly	O
longer	O
in	O
patients	O
treated	O
with	O
GEM	O
-	O
E	O
(	O
median	O
6.77	O
months	O
for	O
GEM	B:C0045093
-	O
E	O
vs.	O
6.68	O
months	O
for	O
GEM	O
,	O
p	O
=	O
0.0977	O
)	O
.	O

Overall	O
survival	O
was	O
not	O
significantly	O
longer	O
in	O
patients	O
treated	O
with	O
GEM	O
-	O
E	O
(	O
median	O
6.77	O
months	O
for	O
GEM	O
-	O
E	B:C1135135
vs.	O
6.68	O
months	O
for	O
GEM	O
,	O
p	O
=	O
0.0977	O
)	O
.	O

Overall	O
survival	O
was	O
not	O
significantly	O
longer	O
in	O
patients	O
treated	O
with	O
GEM	O
-	O
E	O
(	O
median	O
6.77	O
months	O
for	O
GEM	O
-	O
E	O
vs.	O
6.68	O
months	O
for	O
GEM	B:C0045093
,	O
p	O
=	O
0.0977	O
)	O
.	O

Based	O
on	O
this	O
relative	O
effectiveness	O
,	O
the	O
incremental	O
cost	O
per	O
life	O
year	O
gained	O
over	O
GEM	B:C0045093
was	O
estimated	O
at	O
USD	O
70,843.64	O
for	O
GEM	O
-	O
E.	O
GEM	O
-	O
E	O
for	O
pancreatic	O
cancer	I:C0235974
is	O
not	O
more	O
effective	O
than	O
GEM	O
in	O
a	O
real	O
-	O
world	O
setting	O
,	O
and	O
it	O
does	O
not	O
provide	O
reasonable	O
cost	O
-	O
effectiveness	O
over	O
GEM	O
.	O

Based	O
on	O
this	O
relative	O
effectiveness	O
,	O
the	O
incremental	O
cost	O
per	O
life	O
year	O
gained	O
over	O
GEM	O
was	O
estimated	O
at	O
USD	O
70,843.64	O
for	O
GEM	B:C0045093
-	O
E.	O
GEM	O
-	O
E	O
for	O
pancreatic	O
cancer	I:C0235974
is	O
not	O
more	O
effective	O
than	O
GEM	O
in	O
a	O
real	O
-	O
world	O
setting	O
,	O
and	O
it	O
does	O
not	O
provide	O
reasonable	O
cost	O
-	O
effectiveness	O
over	O
GEM	O
.	O

Based	O
on	O
this	O
relative	O
effectiveness	O
,	O
the	O
incremental	O
cost	O
per	O
life	O
year	O
gained	O
over	O
GEM	O
was	O
estimated	O
at	O
USD	O
70,843.64	O
for	O
GEM	O
-	O
E.	B:C1135135
GEM	O
-	O
E	O
for	O
pancreatic	O
cancer	I:C0235974
is	O
not	O
more	O
effective	O
than	O
GEM	O
in	O
a	O
real	O
-	O
world	O
setting	O
,	O
and	O
it	O
does	O
not	O
provide	O
reasonable	O
cost	O
-	O
effectiveness	O
over	O
GEM	O
.	O

Based	O
on	O
this	O
relative	O
effectiveness	O
,	O
the	O
incremental	O
cost	O
per	O
life	O
year	O
gained	O
over	O
GEM	O
was	O
estimated	O
at	O
USD	O
70,843.64	O
for	O
GEM	O
-	O
E.	O
GEM	B:C0045093
-	O
E	O
for	O
pancreatic	O
cancer	I:C0235974
is	O
not	O
more	O
effective	O
than	O
GEM	O
in	O
a	O
real	O
-	O
world	O
setting	O
,	O
and	O
it	O
does	O
not	O
provide	O
reasonable	O
cost	O
-	O
effectiveness	O
over	O
GEM	O
.	O

Based	O
on	O
this	O
relative	O
effectiveness	O
,	O
the	O
incremental	O
cost	O
per	O
life	O
year	O
gained	O
over	O
GEM	O
was	O
estimated	O
at	O
USD	O
70,843.64	O
for	O
GEM	O
-	O
E.	O
GEM	O
-	O
E	B:C1135135
for	O
pancreatic	O
cancer	I:C0235974
is	O
not	O
more	O
effective	O
than	O
GEM	O
in	O
a	O
real	O
-	O
world	O
setting	O
,	O
and	O
it	O
does	O
not	O
provide	O
reasonable	O
cost	O
-	O
effectiveness	O
over	O
GEM	O
.	O

Based	O
on	O
this	O
relative	O
effectiveness	O
,	O
the	O
incremental	O
cost	O
per	O
life	O
year	O
gained	O
over	O
GEM	O
was	O
estimated	O
at	O
USD	O
70,843.64	O
for	O
GEM	O
-	O
E.	O
GEM	O
-	O
E	O
for	O
pancreatic	B:C0235974
cancer	I:C0235974
is	O
not	O
more	O
effective	O
than	O
GEM	O
in	O
a	O
real	O
-	O
world	O
setting	O
,	O
and	O
it	O
does	O
not	O
provide	O
reasonable	O
cost	O
-	O
effectiveness	O
over	O
GEM	O
.	O

Based	O
on	O
this	O
relative	O
effectiveness	O
,	O
the	O
incremental	O
cost	O
per	O
life	O
year	O
gained	O
over	O
GEM	O
was	O
estimated	O
at	O
USD	O
70,843.64	O
for	O
GEM	O
-	O
E.	O
GEM	O
-	O
E	O
for	O
pancreatic	O
cancer	I:C0235974
is	O
not	O
more	O
effective	O
than	O
GEM	B:C0045093
in	O
a	O
real	O
-	O
world	O
setting	O
,	O
and	O
it	O
does	O
not	O
provide	O
reasonable	O
cost	O
-	O
effectiveness	O
over	O
GEM	O
.	O

Based	O
on	O
this	O
relative	O
effectiveness	O
,	O
the	O
incremental	O
cost	O
per	O
life	O
year	O
gained	O
over	O
GEM	O
was	O
estimated	O
at	O
USD	O
70,843.64	O
for	O
GEM	O
-	O
E.	O
GEM	O
-	O
E	O
for	O
pancreatic	O
cancer	I:C0235974
is	O
not	O
more	O
effective	O
than	O
GEM	O
in	O
a	O
real	O
-	O
world	B:C2700280
setting	O
,	O
and	O
it	O
does	O
not	O
provide	O
reasonable	O
cost	O
-	O
effectiveness	O
over	O
GEM	O
.	O

Based	O
on	O
this	O
relative	O
effectiveness	O
,	O
the	O
incremental	O
cost	O
per	O
life	O
year	O
gained	O
over	O
GEM	O
was	O
estimated	O
at	O
USD	O
70,843.64	O
for	O
GEM	O
-	O
E.	O
GEM	O
-	O
E	O
for	O
pancreatic	O
cancer	I:C0235974
is	O
not	O
more	O
effective	O
than	O
GEM	O
in	O
a	O
real	O
-	O
world	O
setting	O
,	O
and	O
it	O
does	O
not	O
provide	O
reasonable	B:C0566251
cost	O
-	O
effectiveness	O
over	O
GEM	O
.	O

Based	O
on	O
this	O
relative	O
effectiveness	O
,	O
the	O
incremental	O
cost	O
per	O
life	O
year	O
gained	O
over	O
GEM	O
was	O
estimated	O
at	O
USD	O
70,843.64	O
for	O
GEM	O
-	O
E.	O
GEM	O
-	O
E	O
for	O
pancreatic	O
cancer	I:C0235974
is	O
not	O
more	O
effective	O
than	O
GEM	O
in	O
a	O
real	O
-	O
world	O
setting	O
,	O
and	O
it	O
does	O
not	O
provide	O
reasonable	O
cost	O
-	O
effectiveness	O
over	O
GEM	B:C0045093
.	O

